Overview
Endo International plc announced that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) Duexis.
Words from Endo International
"We're proud to provide affordable choices to healthcare providers and their appropriate patients while strengthening our reputation as a reliable, quality supplier," said Scott Sims, senior vice president and general manager, injectable solutions & generics at Endo.
Indication
The combination medication is used to relieve the signs and symptoms of rheumatoid arthritis and osteoarthritis while decreasing the risk of developing ulcers of the stomach and upper intestines people may experience from ibuprofen alone.
Sales
According to IQVIA, ibuprofen-famotidine tablet sales were approximately $49 million for the 12 months ended December 31, 2023.
Duexis is a registered trademark of Horizon Therapeutics USA, Inc.
Endo is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies.
